Evogene (EVGN) Raised to “Buy” at ValuEngine

ValuEngine upgraded shares of Evogene (NASDAQ:EVGN) from a hold rating to a buy rating in a research note issued to investors on Wednesday.

EVGN stock remained flat at $$2.95 during trading on Wednesday. 1,152 shares of the company traded hands, compared to its average volume of 4,420. Evogene has a 12-month low of $2.50 and a 12-month high of $4.20.

Evogene (NASDAQ:EVGN) last announced its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.19) earnings per share for the quarter. Evogene had a negative net margin of 961.07% and a negative return on equity of 31.87%. The firm had revenue of $0.38 million during the quarter.

An institutional investor recently raised its position in Evogene stock. ARK Investment Management LLC grew its stake in shares of Evogene Ltd (NASDAQ:EVGN) by 45.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 242,570 shares of the biotechnology company’s stock after acquiring an additional 75,223 shares during the quarter. ARK Investment Management LLC owned about 0.94% of Evogene worth $754,000 at the end of the most recent quarter. 35.19% of the stock is currently owned by institutional investors.

Evogene Company Profile

Evogene Ltd., a biotechnology company, focuses on the enhancement of crop productivity and performance in the United States, Germany, and internationally. It operates through three segments: Evogene, Evofuel, and Biomica. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance.

Featured Article: Day Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply